Acumen Pharma Collaborates with Lonza to Advance Sabirnetug for Alzheimer’s

 

• Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approved
• Sabirnetug is the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer’s disease (AD)
• Acumen is on track to initiate a Phase 2 clinical trial evaluating sabirnetug in the first half of 2024

https://www.biospace.com/article/releases/acumen-pharmaceuticals-collaborates-with-lonza-to-advance-sabirnetug-for-the-treatment-of-alzheimer-s-disease/